Joined February 2020
- Tweets 122
- Following 106
- Followers 150
- Likes 376
4 Photos and videos
Jun 3
Amazing!!
Jun 2
A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.
In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.
While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.
As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”
Congratulations to the researchers and patients who made this important progress possible. 👏👏👏
Video Courtesy: @asco
1
44
Feb 6
Congratulations Moses!! Rising star at DFCI @haematognomist @DanaFarberNews
Award Spotlight: Learn more about H. Moses Murdock, MD, recipient of the ASTCT New Investigator Award, who discusses working toward safe and effective post-transplant maintenance therapies. Read more in Tandem Meeting News: ow.ly/fQ5G50Y9q2J
128
Feb 5
Transplant Jedi. :D @DrCCutler @miguelperales
Congratulations to our 2026 Fellows of ASTCT and past presidents Dr. Corey Cutler and Dr. Miguel-Angel Perales! #Tandem26 @DrCCutler
6
296
22 Dec 2025
Amazing team effort and leadership!! @DrCCutler
22 Dec 2025
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible 1 score in the 2025 @CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day. Learn more: bit.ly/4pHA7EJ
2
94
15 Dec 2025
G.O.A.T. :D
15 Dec 2025
Congratulations to Robert Soiffer, MD, the 2025 recipient of the Edward J. Benz Award for Advancing the Careers of Dana-Farber Faculty. This annual award recognizes a faculty member who goes above and beyond to advance the careers of fellow faculty. We thank Dr. Soiffer for his continued dedication and leadership, which truly exemplify this honor.
2
93
9 Dec 2025
80% 1 year overall survival in mismatched unrelated donor transplants all the way down to 4/8 mismatched donors!! #Donorsforall #solvedisparitieswithscience @BrianShafferMD @BronwenShaw @nmdp_org
9 Dec 2025
Dr. Mahasweta Gooptu (@MGooptu) @danafarber &@nmdp_org presented results using post-transplant cyclophosphamide to prevent graft-versus-host disease in mismatched unrelated donor transplantation, with about 80% 1-year survival thus expanding access to allotransplant for all patients. #ASH25
2
145
CONGRESS | #ASH2025 | POSTER
Mahasweta Gooptu shares results from a Phase II expansion study focusing on PTCy-based GVHD prophylaxis after MMUD PBSC transplantation with reduced-intensity conditioning (N = 193).
The 1-year OS estimate was 79.6%; rates were comparable between HLA 7/8-matched donor recipients and <7/8 matched donor recipients. The 1-year GRFS, 1-year PFS, 1-year CI rate of NRM, and 1-year CI rate of relapse was 49.9%, 70.2%, 12.5%, and 17.3%, respectively.
Follow our live feed for more updates: loom.ly/MbPzIiA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress @MGooptu @DanaFarber
2
1
246
Mahasweta Gooptu retweeted
8 Jul 2025
Donor selection guidelines are out! Grateful to have worked with amazing colleagues and the @CIBMTR and @nmdp_org on this effort. Advances in GVHD prophylaxis support moving beyond strict HLA models toward an integrated approach that brings us closer to a suitable donor for every patient. #ADonorForAll #PTCyRules
Just Published in @ASTCT_Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: sciencedirect.com/science/ar…
3
5
28
2,983
Mahasweta Gooptu retweeted
8 May 2025
1
25
104
6,031
Mahasweta Gooptu retweeted
18 Mar 2025
India’s first indigenous CAR-T therapy is now peer-reviewed in @TheLancetHaem , showing a 73% response rate—marking a breakthrough in accessible, cutting-edge cancer treatment.
2
12
43
1,866
Mahasweta Gooptu retweeted
18 Feb 2025
Congratulations to @DanaFarber researcher Joseph H. Antin, MD, who received the @ASTCT Lifetime Achievement Award during #Tandem25. He was honored for his ongoing contributions to cellular therapy by advancing scientific knowledge in the field.
1
6
19
831
Mahasweta Gooptu retweeted
18 Feb 2025
Congratulations to Joseph Antin, MD, recipient of the @ASTCT Lifetime Achievement Award. This recognition is given to a physician who has made continuing contributions to the BMT and cellular therapy fields through the advancement of knowledge through basic or clinical science.
bit.ly/3X05jmp
1
6
43
3,220
15 Feb 2025
Contributions that cannot be quantified..one of the true pioneering giants in transplantation !! Congratulations Joe Antin :). @DrCCutler @DanaFarberNews
15 Feb 2025
Congratulations, Dr. Antin as @ASTCT Lifetime Achievement Award! Well deserved! 2025 @ASTCT @CIBMTR Tandem Meetings #Tandem25
1
11
665
Mahasweta Gooptu retweeted
6 Feb 2025
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia ashpublications.org/blood/ar…
by Dr. Luskin et al. #leusm #ALL
100% CR.
At day 84, 100% of patients achieved complete cytogenetic remission.
At day 84, 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively.
1
34
133
10,286
Mahasweta Gooptu retweeted
9 Jan 2025
9 Jan 2025
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer:
How I Treat AML relapse after allogeneic HCT:
ashpublications.org/blood/ar…
No one-size fits all approach to this challenging situation, learned a ton writing it!
1
1
8
440
9 Jan 2025
Great experience collaborating with Moses for this review!! Star mentees make our jobs easy :) @haematognomist
9 Jan 2025
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer:
How I Treat AML relapse after allogeneic HCT:
ashpublications.org/blood/ar…
No one-size fits all approach to this challenging situation, learned a ton writing it!
2
7
352
Mahasweta Gooptu retweeted
3 Jan 2025
🚨 New findings from the @BMTCTN 1703 trial: Post-transplant cyclophosphamide (PTCy) lowers patient-reported #GVHD symptom burden vs Tac/MTX in the first year after transplant. 📊🩺 #PTCyRules Congrats, team!! 💪 @GvHD_Meade @MediHumdani
ascopubs.org/doi/10.1200/JCO…
2
16
40
2,954
14 Dec 2024
An instant classic!! Executed by some of the smartest people I know :D @sghmd @GvHD_Meade @MediHumdani @DrMiguelPerales @BrianShafferMD
13 Dec 2024
Two years ago @sghmd presented #BMTCTN1703 at the @ASH_hematology meeting! That was a good day! #PTCyRules @MediHumdani @MGooptu @BrianShafferMD @DrMiguelPerales @AndrewRezvani
1
6
560
5 Dec 2024
Amazing to have been part of this endeavour! #donorsforeveryone
@DrStevenDevine @BrianShafferMD @amjimenezmd @DrMonzrAlMalki @JeffAuletta @spellman_s
5 Dec 2024
.@MGooptu, @DanaFarber, and collaborators confirm a new approach to stem cell transplant donor matching that that expands access to safe hematopoietic stem cell transplants across all racial and ethnic backgrounds.
bit.ly/4fDXiKS
4
13
1,513
Mahasweta Gooptu retweeted
11 Nov 2024
6 Nov 2024
🚨Breaking News/Good News from #ASH24🚨
>90% 1-year OS in PTCy-treated alloHCT recipients age 70 enrolled in @BMTCTN 1703! 😱
Important analysis by @sameem_abedin @MediHumdani @GvHD_Meade and team!! 🙌
ash.confex.com/ash/2024/webp…
#PTCyrules
2
7
837